Please ensure Javascript is enabled for purposes of website accessibility

Pot Stocks Are Wednesday's Big Stock Market Winners. Will They Disappoint Shareholders in the End?

By Dan Caplinger - Updated Feb 3, 2021 at 12:33PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

In a quiet market, marijuana companies stood out.

Wednesday brought a lull for the stock market, as Wall Street consolidated its gains following extremely strong gains on Monday and Tuesday. As of just before noon EST, the Dow Jones Industrial Average (^DJI 1.34%) was down 38 points to 30,649. The S&P 500 (^GSPC 2.02%) rose six points to 3,832, and the Nasdaq Composite (^IXIC 2.76%) moved higher by 28 points to 13,640.

In general, the action in the stock market was relatively quiet. But that was definitely not the case for marijuana stocks, which posted some amazing gains. Let's look more closely at the cannabis industry and what caused investors to be so bullish on Wednesday.

Big gains for big pot stocks

The industry's leaders saw impressive gains in their share prices. Aurora Cannabis (ACB 4.75%) was higher by 8%, while Canopy Growth (CGC 2.79%) weighed in with a 6% gain. Cronos Group (CRON 3.21%) fared even better, rising 9%. Topping the list of top stocks were Tilray (TLRY), up 16%, and Aphria (APHA), climbing 15%, as the two prepare to merge.

Hand holding marijuana leaf, with rows of plants behind.

Image source: Getty Images.

Excitement in the space was prompted, in part, by some merger and acquisition activity. Jazz Phamaceuticals (JAZZ 3.51%) announced that it would acquire cannabinoid drug specialist GW Pharmaceuticals (GWPH) in a deal worth $7.2 billion. According to the terms of the deal, GW investors will receive $220 per share in cash, and that sent GW stock higher by 46%.

Some industry followers hope that the trend toward consolidation will continue. Investors have been pleased at the prospects of the Tilray-Aphria combination, which would create the largest cannabis company by revenue. Other big players could benefit from synergies, and having fewer major players could reduce competitive pressures and improve pricing power.

Marijuana gets a little help from its friends -- in Washington

Meanwhile, another source of the pot-stock push came from legislators in Congress. Senate majority leader Chuck Schumer (D-N.Y.) and other lawmakers announced earlier this week that they would spearhead efforts to jump-start cannabis reform early in 2021. The move follows through on expectations that many marijuana investors had when control of the Senate changed hands following the most recent national elections.

The priority for most pot stocks would be to decriminalize marijuana at the federal level. Even though some companies have been able to operate under accommodative state laws, the fact that federal restrictions remain makes it far harder to run cannabis businesses efficiently. Simple things like business banking are difficult or even impossible under current federal legal restrictions. Even if Congress did nothing more than just get out of the way and let states decide for themselves without federal intervention, it could open the playing field to both global cannabis companies and local players.

Some see federal legalization as a potential source of tax revenue for the government, which would help to narrow large deficits. Yet investors should expect a host of U.S. companies to step up to the plate, challenging Canadian leaders like Aurora and Canopy and creating a whole new competitive dynamic. It may well be that pot legalization will become a case of being careful what you wish for.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GW Pharmaceuticals plc Stock Quote
GW Pharmaceuticals plc
Dow Jones Industrial Average (Price Return) Stock Quote
Dow Jones Industrial Average (Price Return)
$32,654.59 (1.34%) $431.17
S&P 500 Index - Price Return (USD) Stock Quote
S&P 500 Index - Price Return (USD)
$4,088.85 (2.02%) $80.84
NASDAQ Composite Index (Price Return) Stock Quote
NASDAQ Composite Index (Price Return)
$11,984.52 (2.76%) $321.73
Jazz Pharmaceuticals plc Stock Quote
Jazz Pharmaceuticals plc
$152.31 (3.51%) $5.16
Aurora Cannabis Stock Quote
Aurora Cannabis
$3.09 (4.75%) $0.14
Canopy Growth Stock Quote
Canopy Growth
$5.89 (2.79%) $0.16
Cronos Group Stock Quote
Cronos Group
$3.54 (3.21%) $0.11
Tilray Stock Quote
Aphria Stock Quote

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.